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TO THE EDITOR

Figure 1
Morphologic and immunophenotypic features of a representative case. The Wright-Giemsa-stained peripheral blood smear shows no prolymphocytoid morphology among the neoplastc lymphocytes. Four-color flow cytometry demonstrates that nearly all of the leukocytes are an abnormal CD4-positive T cell population with relatively homogeneous expression of CD2, CD3, CD4 and CD7.
We would like to draw attention to rare peripheral blood-and/or marrow-based leukemias of mature T cells which do not fit well within any of the entities included in the new WHO Classification of Lymphoid Neoplasms, and therefore cannot be adequately classified using this system. These have all been CD4-positive, mature T cell lymphoproliferative processes without either the prolymphocytoid morphology or associated hepatosplenomegaly and/or generalized lymphadenopathy characteristic of T cell prolymphocytic leukemia (T-PLL), and without clinical or morphologic features to suggest adult T cell leukemia/lymphoma, mycosis fungoides/Sézary syndrome, T cell large granular lymphocytic leukemia, or an underlying peripheral T cell lymphoma. Because of the rarity of these cases, we have chosen to describe them via this letter, rather than wait the 5 to 10 years likely to be required to accumulate an adequate series for a fulllength manuscript.
In the representative case shown in Figure 1 , a 79-year-old female presented with a WBC count of almost 500 000 per l, yet had no history of cutaneous or peripheral T cell lymphoma, no history of lymphadenopathy or hepatosplenomegaly, no history of emigration from an HTLV-1-endemic area, and no prolymphocytoid morphology among the neoplastic cells. Flow cytometry demonstrated that nearly all of the circulating leukocytes were an abnormal CD3-positive/CD4-positive, mature T cell population. Although cytogenetic evaluation to rule out the characteristic chromosome 14 abnormality of T-PLL was not performed in this case, none of the features suggested a T-PLL, not even the small cell variant. A second case from a 73-yearold male, which demonstrated a lower leukocyte count but otherwise similar features, had cytogenetic analysis demonstrating a normal karyotype.
Under the Revised European-American Lymphoma (REAL) classification previously employed by most hematopathologists, 1 these cases would have fallen within the spectrum of processes known as T cell chronic lymphocytic leukemia/prolymphocytic leukemia (T- Leukemia CLL/PLL), and therefore could have been readily classified for the clinicians treating these patients. However, under the WHO classification the T-CLL component of the REAL's T-CLL/PLL category has been eliminated, 2,3 leaving hematopathologists with only the entity known as T cell prolymphocytic leukemia (T-PLL) for the classification of cases with the clinical and morphologic features described above. Because these cases are more similar to those in a 1995 series of 25 cases of T-CLL 4 than they are to T-PLL, we feel it is important to include an entity comparable to T-CLL in any comprehensive lymphoma classification system. Therefore, the REAL classification appears superior to the WHO system in dealing with these rare cases. While we agree with the WHO's decision to separate T-PLL from T-CLL in light of the cytogenetic evidence arguing that T-PLL is indeed a distinct entity, based on our experience we cannot support the decision to eliminate a T-CLL-like entity.
To those who would favor the WHO classification by arguing that T-CLL represents a 'wastebasket' entity without a definitive biologic underpinning, we would reply that most of the REAL and WHO entities lacking a recurrent cytogenetic abnormality are likely to represent heterogeneous disease processes. For example, nodal diffuse large B cell lymphoma continues to be largely regarded as single entity under the REAL and WHO classifications, despite the recent molecular advances suggesting that DLBCL consists of two or more biologically distinct entities. 5, 6 Because our clinician clients need a framework for making treatment decisions and conducting clinical trials to evaluate new therapies, we strongly believe that the absence of a unifying biological hallmark of T-CLL does not negate the value of having this category until sufficient new clinical and/or biological data warrant refining the concept of T-CLL. TO THE EDITOR Granulocytic sarcoma (GS), also known as chloroma, are extramedullary tumors composed of immature myeloid cells. They have been described in a wide variety of anatomical sites, including breast, ovary, brain, gastrointestinal tract and skull. 1,2 They occur at the onset of acute myelogenous leukemia (AML) or during its evolution. They may also be the first sign of acute transformation of myelodysplastic syndromes and chronic myeloproliferative disorders. They are rarely the first manifestation of AML. GS are observed in only 2 to 8% of AML, mainly of M2 morphology, although they have also been associated with M3, M4, M5, and M7 morphology.
A 37-year-old man was referred to our hospital in June 1999. He had a history of ascitis and intestinal occlusion due to three stenotic lesions of the jejunum. A large peritoneal mass was noted. The patient had surgery in March 1999 during which a partial resection of the proximal jejunum was performed. The histologic examination of the surgical piece was interpreted as a massive lymphomatous infiltration of the whole intestine wall. In May 1999, he had surgery again because of necrosis of the tumor with cutaneous fistula. A bone marrow biopsy and a complete blood count were normal. The patient received two courses of anti-lymphoma chemotherapy.
Because of the lack of response, he was admitted to the hematology service. The patient had ileus, ascitis, severe deterioration of his health status and a 13 kg weight loss. A blood count showed a hemoglobin of 10.5 g/dl, a white blood cell (WBC) count of 4.4 × 10 9 /l and a platelet count of 343 × 10 9 /l. The leukocyte differential showed 84% neutrophils, 15% lymphocytes and 1% monocytes.
A review of the original histology found the malignant cells to be blasts. These cells were shown to contain myeloperoxidase and to express CD34 and CD68 antigens. Furthermore, immunophenotyping was partially positive for CD15 and lysozyme. A retrospective diagnosis of isolated granulocytic sarcoma was made. Unfortunately, no material was available for cytogenetic studies.
The bone marrow aspirate and the blood cell count were still normal. At the end of July 1999, chemotherapy with aracytidine and idarubicin was started, leading to the disappearance of all abdominal signs and a complete remission. No complementary radiotherapy was performed because of the small bowel localization of the granulocytic sarcoma. Then, the patient received a consolidation therapy with high doses of aracytidine and idarubicin. In December 1999, after preparative regimen by BEAM, he had an autologous bone marrow transplantation. No marrow involvement by acute myelogenous leukemia was detected.
Hematopoietic reconstruction was incomplete, without any signs of acute leukemia. The patient was hospitalized again at the end of August 2000 because of the presence of 39% circulating blasts. A bone marrow aspirate showed hypercellularity with 72% myeloblasts, some containing Auer rods and showing discrete abnormal granular maturation, leading to the diagnosis of AML type 2. The blasts were positive for CD13, CD34, CD117, and myeloperoxidase, but negative for lysozyme, CD35, and CD15.
A second complete remission was obtained after an induction course consisting of aracytidine and idarubicin followed, at day 15, by high-dose aracytidine and amsacrine because of the persistence of 15% blasts in the bone marrow. The abdomen remained normal. In April 2001, the patient received an allogenic bone marrow transplantation from an HLA-identical familial donor after conditioning using total body radiation (12 Gy) and cyclophosphamide (120 mg/kg). Hematopoietic reconstruction was complete but the patient presented an early acute intestinal graft-versus-host disease requiring immunosuppressive therapy. Complete hematopoietic chimerism was confirmed by cytogenetic analysis. The patient remained in complete remission until December 2001, at which time he developed a meningeal relapse of AML without medullary involvement.
Cytogenetic analysis of the patient's bone marrow cells was performed at the time of diagnosis of AML type 2. The chromosomes were R-banded. We analyzed 25 metaphases: three were 46,XY, one 47,XY,+9, inv(16)(p13q22), 19 48,XY,+9, inv(16)(p13q22), +22 and (Figure 1 ) two 49,XYY,+9, inv(16)(p13q22), +22. The FISH study using partial chromosome paint 16p (pcp(16p) Oncor, Illkirch, France) confirmed the presence of the inv(16) in all the metaphases with trisomy 22 and/or trisomy 9.
The patient reported here is one of the rare cases in which granulocytic sarcoma preceded the onset of overt acute myelogenous leukemia. [2] [3] [4] In their analysis of the effect of early antileukemic therapy in isolated chloroma, Imrie et al 5 found 83 published cases and added seven of their own. 4 They showed that chemotherapy given at diagnosis of GS delayed the onset of AML (median: 36 months vs 6 months for non-chemotherapy) and was associated with a better survival. More than half of the patients were still alive with a median followup of 25 months, compared to a median survival of 13 months for those who did not receive chemotherapy. The interval between diagnosis of GS and diagnosis of AML was 17 months in our patient, who is still alive 30 months after GS was diagnosed.
The best results were obtained when anti-AML chemotherapy was started at the diagnosis of GS. Unfortunately, in many cases, the cell morphology resembles large cell lymphoma, which may lead to mis-
